Rituximab for the treatment of refractory anti-glomerular basement membrane disease.
Rituximab
anti-glomerular basement membrane disease
refractory
severe
Journal
Renal failure
ISSN: 1525-6049
Titre abrégé: Ren Fail
Pays: England
ID NLM: 8701128
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
entrez:
12
7
2022
pubmed:
13
7
2022
medline:
15
7
2022
Statut:
ppublish
Résumé
Anti-glomerular basement membrane (anti-GBM) disease is a rare but severe autoantibody-mediated immune disorder. The typical clinical presentation includes rapidly progressive glomerulonephritis and often concurrent pulmonary hemorrhage. The present study is aimed to investigate the therapeutic effects of rituximab either used alone or with other immunosuppressants. Eight patients diagnosed with anti-GBM disease and treated with rituximab from 2014 to 2020 were retrospectively reviewed. Eight patients included 5 males and 3 females with a median age of 58.5 years. They all presented severe kidney injuries and 1 patient had lung hemorrhage. At diagnosis, the median of serum creatinine was 246 µmol/L (ranging from 91 to 850 µmol/L), with 3 patients requiring dialysis. All of them received corticosteroids and plasmapheresis. Rituximab was given as either standard four weekly doses or one pulse ranging from 100 to 600 mg. After a median follow-up of 34.5 months, kidney function was partially recovered or stabilized in 5/8 (62.5%) patients, free of dialysis. Anti-GBM antibodies remained undetected in all patients during follow-up. No severe adverse effect associated with rituximab was observed. Rituximab may be an alternative therapy in the treatment of patient with severe or refractory anti-GBM disease.
Sections du résumé
BACKGROUND
UNASSIGNED
Anti-glomerular basement membrane (anti-GBM) disease is a rare but severe autoantibody-mediated immune disorder. The typical clinical presentation includes rapidly progressive glomerulonephritis and often concurrent pulmonary hemorrhage. The present study is aimed to investigate the therapeutic effects of rituximab either used alone or with other immunosuppressants.
METHODS
UNASSIGNED
Eight patients diagnosed with anti-GBM disease and treated with rituximab from 2014 to 2020 were retrospectively reviewed.
RESULTS
UNASSIGNED
Eight patients included 5 males and 3 females with a median age of 58.5 years. They all presented severe kidney injuries and 1 patient had lung hemorrhage. At diagnosis, the median of serum creatinine was 246 µmol/L (ranging from 91 to 850 µmol/L), with 3 patients requiring dialysis. All of them received corticosteroids and plasmapheresis. Rituximab was given as either standard four weekly doses or one pulse ranging from 100 to 600 mg. After a median follow-up of 34.5 months, kidney function was partially recovered or stabilized in 5/8 (62.5%) patients, free of dialysis. Anti-GBM antibodies remained undetected in all patients during follow-up. No severe adverse effect associated with rituximab was observed.
CONCLUSION
UNASSIGNED
Rituximab may be an alternative therapy in the treatment of patient with severe or refractory anti-GBM disease.
Identifiants
pubmed: 35820833
doi: 10.1080/0886022X.2022.2097405
pmc: PMC9291707
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1123-1129Références
BMJ Case Rep. 2014 Nov 24;2014:
pubmed: 25422333
J Bras Nefrol. 2020 Mar;42(1):77-93
pubmed: 31904761
Kidney Int Rep. 2018 May 08;3(5):1229-1232
pubmed: 30197991
J Autoimmun. 2014 Feb-Mar;48-49:108-12
pubmed: 24456936
Ann Intern Med. 2001 Jun 5;134(11):1033-42
pubmed: 11388816
J Autoimmun. 2015 Jun;60:74-9
pubmed: 25953709
Clin Kidney J. 2017 Aug;10(4):461-469
pubmed: 28852482
Ren Fail. 2021 Dec;43(1):79-89
pubmed: 33334228
Nat Rev Nephrol. 2011 Jul 19;7(12):697-705
pubmed: 21769105
Kidney Int. 1999 Nov;56(5):1638-53
pubmed: 10571772
NDT Plus. 2010 Aug;3(4):421-2
pubmed: 25949452
Nephrol Dial Transplant. 2008 Oct;23(10):3126-9
pubmed: 18413431
Ren Fail. 2021 Dec;43(1):149-155
pubmed: 33435789
Semin Arthritis Rheum. 2013 Jun;42(6):567-72
pubmed: 23352254
Medicine (Baltimore). 2019 Nov;98(44):e17801
pubmed: 31689860
BMJ Case Rep. 2021 Apr 1;14(4):
pubmed: 33795274
QJM. 2012 Feb;105(2):195-7
pubmed: 21258056
Ann Rheum Dis. 2002 Oct;61(10):922-4
pubmed: 12228164
Kidney Int Rep. 2018 Dec 17;4(4):614-618
pubmed: 30993238
Clin Kidney J. 2014 Feb;7(1):53-6
pubmed: 25859351
Kidney Int. 2021 Oct;100(4):753-779
pubmed: 34556300
NDT Plus. 2009 Jun;2(3):225-7
pubmed: 25983996
BMC Nephrol. 2011 May 13;12:21
pubmed: 21569485
BMC Nephrol. 2018 Sep 20;19(1):241
pubmed: 30236081